• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

Opinion
Video

A urologist discusses the prospective advantages of the novel gene therapy nadofaragene firadenovec compared to standard-of-care therapies for patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) and highlights the significance of the reported 5-year bladder preservation and overall survival rates.

Related Videos
Dr Brian Mulherin
Dr Brian Koffman
Dr Brian Mulherin
Dr Vivek Subbiah
Dr Scott Soefje
Dr Scott Soefje
Dr Mark Fendrick
Dr Vishnukamal Golla
Dr Sophia Humphreys
Dr Vivek Subbiah
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.